AstraZeneca praises AstraZeneca’s ‘breakthrough’ antibody treatment for Covid patients at high risk.


AstraZeneca applauds a ‘breakthrough’ antibody treatment for Covid patients at high risk.

Trial results show that an antibody cocktail can reduce the risk of severe illness and death in those who are most vulnerable to vaccines.

According to trial results, an antibody cocktail developed by AstraZeneca can significantly reduce the risk of Covid-19-related hospitalization and death in the most vulnerable people who may have a reduced immune response to vaccination.

When compared to a placebo, one dose of the treatment, known as AZD7442, reduced the risk of developing symptomatic Covid-19 by 83 percent, with no severe disease or deaths.

When treated within three days of the onset of symptoms, people given a higher dose had an 88 percent lower risk of severe Covid-19 or death.

The antibody cocktail was “generally well tolerated” in both groups, according to AstraZeneca, and there were no new safety concerns discovered.

The findings suggest that a breakthrough is on the way for the 2% of the world’s population who are thought to be at higher risk of a poor response to the Covid-19 vaccine.

Patients on dialysis, those on medication after an organ transplant, and those on immunosuppressive drugs for conditions such as multiple sclerosis and rheumatoid arthritis are all included in this group.

It’s the first phase III trial to assess a class of drugs known as monoclonal antibodies in high-risk and immunocompromised patients.

Phase III trials compare a new treatment to an existing one or a placebo in larger groups of sick people.

More than 75% of trial participants had multiple health issues, putting them at high risk of developing severe Covid-19 if they became infected.

AstraZeneca is one of the largest pharmaceutical companies to have developed monoclonal antibodies to treat coronavirus.

Monoclonal antibodies created in a lab are used to fight infections in the same way that natural antibodies are used.

They are different from vaccines in that they do not rely on the body to produce an immune response, and thus can help people with weak or compromised immune systems.

AstraZeneca asked US regulators for emergency use approval for the therapy as a preventative drug last month.

It announced a week later that it would also submit the new treatment data to international health authorities.

The European Medicines Agency (EMA) announced that it had begun a real-time review of the therapy.

Professor of intensive care, Hugh Montgomery.

News summary from Infosurhoy in the United Kingdom.

AstraZeneca applauds a ‘breakthrough’ antibody treatment for Covid patients at high risk.

charset=”utf-8″ wpcc-script async src=”” wpcc-script async src=”” wpcc-script async src=”https

AstraZeneca hails ‘breakthrough’ antibody treatment for high-risk Covid patients

AstraZeneca hails ‘breakthrough’ antibody treatment for high-risk Covid patients

Comments are closed.